Volume 28, Issue 165 (10-2018)
J Mazandaran Univ Med Sci 2018, 28(165): 57-68 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hosseini S S, Keyhanian S, Vosoughi E, Ahangar N. Polymorphisms of CYP1A1 Gene Variants m1 and m2 and Their Association with the Incidence of Cancer in West of Mazandaran Province, Iran. J Mazandaran Univ Med Sci 2018; 28 (165) :57-68
URL: http://jmums.mazums.ac.ir/article-1-11287-en.html
URL: http://jmums.mazums.ac.ir/article-1-11287-en.html
Abstract: (3179 Views)
Background and purpose: The aim of this study was to determine the genetic variability of CYP1A1 m1 and m2 polymorphisms in cancer patients compared with healthy population in the west of Mazandaran province, Iran.
Materials and methods: A case-control study was carried out in 120 non-relative healthy volunteers (60 males and 60 females) and 84 non-relative patients (39 males and 46 females) with diagnosis of cancer, attending the Hematology/Oncology ward in Ramsar Imam Sajjad Hospital between July 2016 and December 2017. Peripheral blood samples (3ml) were taken from the participants and stored at -20°C. The PCR-RFLP method was used to determine the distribution of CYP1A1 gene polymorphisms.
Results: Among the two gene variants m1 and m2, individuals with AG and GG genotypes of CYP1A1 m2 polymorphism were found to have a significantly higher and increased risk for cancer (OR=3.94, 95%CI=2.05-7.57, P= 0.00, OR=9.46 , 95%CI=1.92-46.49, P= 0.00, respectively) and the TC genotype of CYP1A1 m1 polymorphism also had a significantly higher and increased risk for cancer (OR= 2.6 , 95% CI = 1.4-4.6, P=0.00). The ‘G’ allele was detected to have a strong association with cancer (P<0.001). The ‘C’ allele also showed strong association with the incidence of cancer (P<0.001). Thus, both CYP1A1 m1 and m2 polymorphisms showed an increased risk for cancer.
Conclusion: Our study suggested that the presence of ‘C’ allele of m1 polymorphism and ‘G’ allele of m2 polymorphism as the leading alleles that increase cancer susceptibility in the studied population.
Materials and methods: A case-control study was carried out in 120 non-relative healthy volunteers (60 males and 60 females) and 84 non-relative patients (39 males and 46 females) with diagnosis of cancer, attending the Hematology/Oncology ward in Ramsar Imam Sajjad Hospital between July 2016 and December 2017. Peripheral blood samples (3ml) were taken from the participants and stored at -20°C. The PCR-RFLP method was used to determine the distribution of CYP1A1 gene polymorphisms.
Results: Among the two gene variants m1 and m2, individuals with AG and GG genotypes of CYP1A1 m2 polymorphism were found to have a significantly higher and increased risk for cancer (OR=3.94, 95%CI=2.05-7.57, P= 0.00, OR=9.46 , 95%CI=1.92-46.49, P= 0.00, respectively) and the TC genotype of CYP1A1 m1 polymorphism also had a significantly higher and increased risk for cancer (OR= 2.6 , 95% CI = 1.4-4.6, P=0.00). The ‘G’ allele was detected to have a strong association with cancer (P<0.001). The ‘C’ allele also showed strong association with the incidence of cancer (P<0.001). Thus, both CYP1A1 m1 and m2 polymorphisms showed an increased risk for cancer.
Conclusion: Our study suggested that the presence of ‘C’ allele of m1 polymorphism and ‘G’ allele of m2 polymorphism as the leading alleles that increase cancer susceptibility in the studied population.
Type of Study: Research(Original) |
Subject:
Pharmacy
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
